By Counterforce Health Team in Aldurazyme (laronidase) —

UnitedHealthcare's Coverage Criteria for Aldurazyme (laronidase) in Washington: What Counts as "Medically Necessary"?

Answer Box: Getting Aldurazyme Covered by UnitedHealthcare in Washington

UnitedHealthcare requires prior authorization for Aldurazyme (laronidase) across all plan types. To get approved, you need confirmed MPS I diagnosis with enzyme testing, genetic confirmation, and a specialist prescriber. Submit through the UHC Provider Portal with complete lab results and medical necessity letter. If denied, Washington residents can appeal internally, then request external review through an Independent Review Organization within 180 days. Start today: Gather your enzyme assay results, genetic testing, and specialist notes before submitting your PA request.

Table of Contents

  1. Policy Overview: How UnitedHealthcare Covers Aldurazyme
  2. Medical Necessity Requirements
  3. Step Therapy and Exceptions
  4. Required Diagnostics and Documentation
  5. Site of Care and Specialty Pharmacy Requirements
  6. Evidence to Support Medical Necessity
  7. Sample Medical Necessity Narrative
  8. Appeals Process in Washington
  9. Cost Assistance and Savings Options
  10. FAQ

Policy Overview: How UnitedHealthcare Covers Aldurazyme

UnitedHealthcare treats Aldurazyme (laronidase, J1931) as a high-cost specialty biologic requiring prior authorization across all major product lines:

  • Commercial plans (employer-sponsored)
  • Medicare Advantage
  • Medicaid/Community Plans (Apple Health in Washington)

Where to Find Official Coverage Policies

UnitedHealthcare publishes coverage criteria in their Medical Drug Policy for Enzyme Replacement Therapy. This policy specifically covers Aldurazyme as a "proven" treatment for MPS I when medical necessity criteria are met.

Note: Policy details can vary by plan type and state. Always verify current requirements through the UHC Provider Portal for your specific member.

Medical Necessity Requirements

Core Clinical Criteria

UnitedHealthcare requires all of the following elements for Aldurazyme approval:

Requirement What UHC Needs Documentation
Confirmed MPS I Diagnosis IDUA enzyme deficiency below normal range CLIA-certified lab report with reference ranges
Genetic Confirmation Pathogenic/likely pathogenic IDUA variants Molecular genetics report with variant classification
Specialist Oversight Metabolic geneticist or lysosomal disease expert Provider credentials and attestation letter
FDA-Approved Indication Non-neuronopathic MPS I (Hurler, Hurler-Scheie, Scheie) Clinical notes documenting phenotype
Appropriate Dosing 0.58 mg/kg weekly IV per FDA label Treatment plan with weight-based calculations

Baseline Clinical Assessment

Your medical necessity letter should document:

  • Organ involvement: Hepatosplenomegaly, cardiac valve disease, joint contractures
  • Functional limitations: Reduced endurance, sleep apnea, hearing loss
  • Disease progression risk: Without treatment, expected morbidity and mortality
  • Treatment goals: Stabilize respiratory function, reduce organomegaly, improve mobility

Step Therapy and Exceptions

Good news: Step therapy typically does not apply to Aldurazyme because it's the only FDA-approved enzyme replacement therapy for MPS I. UnitedHealthcare's policy acknowledges that "no formulary alternative enzyme-replacement therapy exists for MPS I."

When Step Therapy Might Apply

In rare cases, UHC may require documentation that:

  • Hematopoietic stem cell transplant (HSCT) was considered but deemed inappropriate
  • Patient-specific factors make HSCT unsuitable (age, comorbidities, donor availability)

Medical Exception Pathways

If step therapy is incorrectly applied, request an exception by documenting:

  • Contraindication: Medical reasons preventing alternative treatments
  • Clinical urgency: Progressive disease requiring immediate ERT initiation
  • Specialist recommendation: Clear statement that Aldurazyme is first-line therapy

Required Diagnostics and Documentation

Essential Lab Results

Submit complete reports from CLIA-certified laboratories:

Enzyme Testing:

  • α-L-iduronidase activity in leukocytes, fibroblasts, or dried blood spot
  • Must show activity below laboratory's normal reference range
  • Include specimen type, assay method, and reference ranges

Genetic Testing:

  • IDUA gene sequencing or lysosomal storage disease panel
  • Pathogenic or likely pathogenic variants per ACMG criteria
  • Include full laboratory report with variant classification

Supporting Tests:

  • Urinary glycosaminoglycans (elevated dermatan and heparan sulfate)
  • Baseline organ function assessments (echo, PFTs, sleep study)

Documentation Timeline Requirements

  • Lab results must be within 12 months of PA submission
  • Older results may require repeat testing
  • Genetic testing results remain valid indefinitely once confirmed
Tip: Order both enzyme and genetic testing simultaneously to avoid delays. Some labs offer MPS panels that include both tests.

Site of Care and Specialty Pharmacy Requirements

UnitedHealthcare's Site of Care Policy

UHC applies cost-management rules that may require infusion in lower-cost settings:

Preferred Sites:

  • Physician office infusion centers
  • Freestanding infusion centers
  • Home infusion (when clinically appropriate)

Hospital Outpatient Requires Additional Justification:

  • History of severe infusion reactions
  • Significant comorbidities requiring hospital-level monitoring
  • Unstable condition with high reaction risk

OptumRx Specialty Pharmacy Requirements

Many UHC plans require Aldurazyme to be dispensed through Optum Specialty Pharmacy rather than "buy and bill" by the provider. This "white-bagging" approach requires:

  • Patient enrollment with Optum Specialty
  • Drug shipped to infusion site with proper cold-chain handling
  • Coordination between pharmacy and infusion center

Evidence to Support Medical Necessity

Clinical Guidelines to Reference

FDA Prescribing Information:

  • Aldurazyme is indicated for MPS I patients with non-neuronopathic disease
  • Weekly 0.58 mg/kg IV dosing is standard of care
  • Access FDA label

GeneReviews Consensus:

  • ERT is first-line therapy for attenuated MPS I (Hurler-Scheie, Scheie)
  • Early initiation recommended to prevent disease progression
  • Reference NCBI GeneReviews

Objective Measures of Benefit

For renewals, document improvements or stabilization in:

  • 6-minute walk test results
  • Pulmonary function tests
  • Echocardiogram findings (valve function, cardiac size)
  • Sleep study results (apnea-hypopnea index)
  • Joint range of motion measurements

Sample Medical Necessity Narrative

Patient has confirmed mucopolysaccharidosis type I (MPS I) based on markedly reduced α-L-iduronidase enzyme activity of [X] nmol/hr/mg protein (normal range: [Y-Z]) and pathogenic biallelic IDUA variants [specify variants]. Clinical presentation includes hepatosplenomegaly, cardiac valve disease, joint contractures, and obstructive sleep apnea consistent with MPS I phenotype. Aldurazyme (laronidase) at 0.58 mg/kg weekly IV is the only FDA-approved enzyme replacement therapy for MPS I and represents standard-of-care treatment to prevent disease progression. Treatment goals include stabilizing respiratory function, reducing organomegaly, and improving functional capacity. Patient will be monitored with serial echocardiograms, pulmonary function tests, and functional assessments per established MPS I management guidelines.

Appeals Process in Washington

Internal Appeals with UnitedHealthcare

Standard Appeals:

  • File within 180 days of denial notice
  • Submit through UHC Provider Portal or by mail/fax
  • Decision typically within 30 days for standard review
  • Include additional documentation: updated lab results, specialist letters, peer-reviewed studies

Expedited Appeals:

  • For urgent medical situations where delay could jeopardize health
  • Decision within 72 hours
  • Required for time-sensitive medications like Aldurazyme

External Review in Washington State

If internal appeals fail, Washington residents can request Independent Review Organization (IRO) review:

Timeline: 180 days from final internal denial to request external review Process: Submit request to Washington State Office of the Insurance Commissioner Decision: IRO must decide within 30 days (72 hours for expedited) Binding: IRO decisions are binding on the insurer

Contact Washington Insurance Commissioner:

From our advocates: We've seen several Washington families successfully overturn UnitedHealthcare denials for rare disease medications through the external review process. The key is submitting comprehensive clinical documentation and citing specific policy language that supports coverage. Don't give up after the first denial—Washington's consumer protection laws are strong.

Cost Assistance and Savings Options

Manufacturer Support Programs

Sanofi CareConnect PSS:

  • Copay assistance up to $15,000/year for eligible commercial members
  • Medicare/Medicaid patients typically not eligible due to federal rules
  • Apply at Sanofi patient support

Foundation Grants

  • National Organization for Rare Disorders (NORD) Patient Assistance Programs
  • HealthWell Foundation (when funds available)
  • Patient Access Network Foundation

Washington State Resources

  • Apple Health (Medicaid) may provide coverage for eligible low-income residents
  • Washington Prescription Drug Program for additional savings

Counterforce Health helps patients navigate the complex prior authorization and appeals process for specialty medications like Aldurazyme. Our platform analyzes denial letters and creates targeted, evidence-based appeals that align with each insurer's specific requirements, increasing the likelihood of approval while saving time for patients and providers.

FAQ

How long does UnitedHealthcare prior authorization take for Aldurazyme in Washington? Standard PA review typically takes 72 hours after receipt of complete documentation. Expedited review (for urgent cases) is usually completed within 24 hours.

What if Aldurazyme is non-formulary on my UHC plan? Even if non-formulary, UHC must cover medically necessary treatments. Submit a formulary exception request with strong clinical justification and specialist support.

Can I request an expedited appeal if my Aldurazyme is denied? Yes, if delaying treatment could jeopardize your health or ability to regain function. Washington law requires insurers to process expedited appeals within 72 hours.

Does step therapy apply if I've tried other treatments outside Washington? Step therapy generally doesn't apply to Aldurazyme since it's the only FDA-approved ERT for MPS I. However, document any relevant treatment history in your PA request.

What happens if my appeal is denied by UnitedHealthcare? You can request external review through Washington's Independent Review Organization (IRO) system. File within 180 days of the final internal denial.

Do I need to use Optum Specialty Pharmacy for Aldurazyme? Many UHC plans require specialty pharmacy sourcing through Optum. Check your specific plan requirements and coordinate with your infusion center.

How often do I need to renew my Aldurazyme prior authorization? Typically every 12 months, though some plans may require more frequent reviews. Renewal requests should include objective evidence of clinical benefit.

What if my doctor isn't a metabolic specialist? UHC typically requires oversight by a metabolic geneticist or lysosomal disease specialist. Your primary doctor may need to consult with or refer to an appropriate specialist.

When to Escalate

Contact the Washington State Office of the Insurance Commissioner if:

  • UHC fails to meet appeal deadlines
  • You suspect improper denial practices
  • The external review process isn't working properly

Washington Insurance Commissioner:

For complex cases involving multiple denials or policy interpretation issues, consider working with Counterforce Health to develop a comprehensive appeals strategy that addresses UnitedHealthcare's specific coverage criteria while leveraging Washington's strong consumer protection laws.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice or legal counsel. Coverage decisions depend on individual plan terms, clinical circumstances, and current policies. Always consult with your healthcare provider about treatment decisions and verify current coverage requirements with your insurer. For personalized assistance with prior authorizations and appeals, consider consulting with patient advocacy services or legal professionals specializing in healthcare coverage.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.